RxDoctor Payments Data

Laura Smith

Family · Middletown, PANPI 1912374067

Payments from drug & device makers

$1,215in general payments, 2019–2025

Across 80 payments — averaging $15.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$221
  • Lilly USA, LLC$173
  • Boehringer Ingelheim$147
  • Pfizer$143
  • Novo Nordisk$113
  • GSK$92
  • plus $326 from 12 others

What the payments were for

  • Food & beverage$1,214100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,215 in reported general payments places this provider in the 75th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$38,516
Medicare patients
179
Services billed
517

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin64$72,339
EliquisApixaban50$59,190
MounjaroTirzepatide25$40,506
OzempicSemaglutide30$40,250
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$36,699
RybelsusSemaglutide17$32,877
TrulicityDulaglutide12$27,073
UbrelvyUbrogepant12$17,256
MyrbetriqMirabegron22$13,297
Breo ElliptaFluticasone/Vilanterol17$11,090
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$9,848
Atorvastatin Calcium343$4,971
Albuterol Sulfate HfaAlbuterol Sulfate113$4,476
Bevespi AerosphereGlycopyrrolate/Formoterol Fum11$4,444
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate19$3,185

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$113$73,12647 claims
Boehringer IngelheimJardiance$147$72,33964 claims
Lilly USA, LLCMounjaro, Trulicity$173$67,57937 claims
PfizerEliquis$143$59,19050 claims
GSKTrelegy Ellipta, Breo Ellipta$92$47,78860 claims
AbbVieUbrelvy$221$17,25612 claims
AstraZenecaBevespi Aerosphere$35$4,44411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,717 family providers in Pennsylvania.

Other family in Middletown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →